HCPLive Network

Extended Sleep Time Linked to Reduced Pain Sensitivity

 
WEDNESDAY, Dec. 5 (HealthDay News) -- Extending bedtime for sleepy healthy adults reduces daytime sleepiness and correlates with reduced pain sensitivity, according to a study published in the Dec. 1 issue of SLEEP.

Timothy A. Roehrs, Ph.D., of the Sleep Disorders and Research Center at the Henry Ford Hospital in Detroit, and colleagues conducted a study involving 18 health volunteers who had an average daily sleep latency of less than 8 minutes on the multiple sleep latency test (MSLT). Participants were randomized to four nights of extended sleep (10 hours per night) or four nights of their regular bedtime. Daytime sleepiness was measured on days one and four using the MSLT, and pain sensitivity was assessed using finger withdrawal latency pain testing to a radiant heat stimulus.

The researchers found that those in the extended sleep group slept an average of 1.8 hours more per night compared with those who continued their usual regular bedtime, and their average daily sleep latency increased on the MSLT. In the extended sleep group, finger withdrawal latency was also increased, indicative of a reduction in pain sensitivity. During the four experimental nights, the increase in sleep time correlated with improvement on the MSLT, which was associated with decreased sensitivity to pain.

"The current results suggest that the increased pain sensitivity of the sleepy individuals is the result of their underlying sleepiness, which the results of this study show is a state and not a trait phenomenon," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Further Reading
Complication rates are similar for single-level anterior cervical discectomy and fusions, whether the procedure is performed by a neurosurgeon or orthopedic surgeon, according to a study published in the Sept. 15 issue of Spine.
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
More Reading